Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

Item
http://www.wikidata.org/entity/Q33396001
Infections in myelodysplastic syndromesPolish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesEfficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletionDendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.Update on the pharmacotherapy for myelodysplastic syndromes.Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
P2860

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

Item
http://www.wikidata.org/entity/Q33396001
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Treatment by Lenalidomide in l ...... deletion--the GFM experience.
@ast
Treatment by Lenalidomide in l ...... deletion--the GFM experience.
@en
type
label
Treatment by Lenalidomide in l ...... deletion--the GFM experience.
@ast
Treatment by Lenalidomide in l ...... deletion--the GFM experience.
@en
prefLabel
Treatment by Lenalidomide in l ...... deletion--the GFM experience.
@ast
Treatment by Lenalidomide in l ...... deletion--the GFM experience.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Treatment by Lenalidomide in l ...... deletion--the GFM experience.
@en
P2093
P304
P31
P356
10.1016/J.LEUKRES.2011.05.034
P433
P478
P50
P577
P698